Inhalation injury severity and systemic immune perturbations in burned adults

Annals of Surgery

Volumn 257, Issue 6, 2013, Pages 1137-1146

  Davis, Christopher S ^a   Janus, Scott E ^a   Mosier, Michael J ^a   Carter, Stewart R ^a   Gibbs, Jeffrey T ^a   Ramirez, Luis ^a   Gamelli, Richard L ^a   Kovacs, Elizabeth J ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Burn; Chemokines; Cytokines; Growth factors; Inhalation injury; Interleukin 1 receptor antagonist; Mortality

Indexed keywords

EOTAXIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 15; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; BODY SURFACE; BRONCHOSCOPY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; INJURY SEVERITY; INTENSIVE CARE; LUNG BURN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE;

BIOLOGICAL MARKERS; BRONCHOSCOPY; BURNS, INHALATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOASSAY; INJURY SEVERITY SCORE; INTENSIVE CARE UNITS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC;

EID: 84879077997     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318275f424     Document Type: Article

References (92)

1. Pruitt BA, Wolf SE, Mason AD. Epidemiological, demographic, and outcome characteristics of burn injury. In: Herndon DN, ed. Total Burn Care, 3rd ed. Philadelphia: Elsevier; 2007:14-32.
2. Latenser BA, Miller SF, Bessey PQ, et al. National Burn Repository 2006: a ten-year review. J Burn Care Res. 2007;28:635-658.
3. Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. J Exp Med. 2011;208:2581-2590.
4. Albright JM, Davis CS, Bird MD, et al. The acute pulmonary inflammatory response to the graded severity of smoke inhalation injury. Crit Care Med. 2012;40:1113-1121.
5. Davis CS, Albright JM, Carter SR, et al. Early pulmonary immune hyporesponsiveness is associated with mortality after burn and smoke inhalation injury. J Burn Care Res. 2012;33:26-35.
6. Osler T, Glance LG, Hosmer DW. Simplified estimates of the probability of death after burn injuries: extending and updating the Baux score. J Trauma. 2010;68:690-697.
7. Greenhalgh DG, Saffle JR, Holmes JH, et al. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res. 2007;28:776-790.
8. Endorf FW, Gamelli RL. Inhalation injury, pulmonary perturbations, and fluid resuscitation. J Burn Care Res. 2007;28:80-83.
9. Bird MD, Zahs A, Deburghgraeve C, et al. Decreased pulmonary inflammation following ethanol and burn injury in mice deficient in TLR4 but not TLR2 signaling. Alcohol Clin Exp Res. 2010;34:1733-1741.
10. Ivy ME, Atweh NA, Palmer J, et al. Intra-abdominal hypertension and abdominal compartment syndrome in burn patients. J Trauma. 2000;49:387-391.
11. Miller SF, Bessey P, Lentz CW, et al. ABA NBR Committee. National burn repository 2007 report: a synopsis of the 2007 call for data. J Burn Care Res. 2008;29:862-870; discussion 871.
12. Hassan Z, Wong JK, Bush J, et al. Assessing the severity of inhalation injuries in adults. Burns. 2010;36:212-216.
13. Klein MB, Hayden D, Elson C, et al. The association between fluid administration and outcome following major burn: a multicenter study. Ann Surg. 2007;245:622-628.
14. Mosier MJ, Pham TN, Klein MB, et al. Early acute kidney injury predicts progressive renal dysfunction and higher mortality in severely burned adults. J Burn Care Res. 2010;31:83-92.
15. Coca SG, Bauling P, Schifftner T, et al. Contribution of acute kidney injury toward morbidity and mortality in burns: a contemporary analysis. Am J Kidney Dis. 2007;49:517-523.
16. Mosier MJ, Pham TN, Park DR, et al. Predictive value of bronchoscopy in assessing the severity of inhalation injury. J Burn Care Res. 2012;33:65-73.
17. Fisher CJ, Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994;271:1836-1843.
18. Fisher CJ, Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 1996;334:1697-1702.
19. Opal SM, Fisher CJ, Jr, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebocontrolled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997;25:1115-1124.
20. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med. 2001;29:S121-S125.
21. Deans KJ, Haley M, Natanson C, et al. Novel therapies for sepsis: a review. J Trauma. 2005;58:867-874.
22. Schr̈oder O, Laun RA, Held B, et al. Association of interleukin-10 promoter polymorphism with the incidence of multiple organ dysfunction following major trauma: results of a prospective pilot study. Shock. 2004;21:306-310.
23. Schroeder O, Schulte KM, Schroeder J, et al. The-1082 interleukin-10 polymorphism is associated with acute respiratory failure after major trauma: a prospective cohort study. Surgery. 2008;143:233-242.
24. Huebinger RM, Rivera-Chavez F, Chang LY, et al. IL-10 polymorphism associated with decreased risk for mortality after burn injury. J Surg Res. 2010;164:e141-e145.
25. Gu W, Zeng L, Zhou J, et al. Clinical relevance of 13 cytokine gene polymorphisms in Chinese major trauma patients. Intensive Care Med. 2010;36:1261-1265.
26. McDaniel DO, Hamilton J, Brock M, et al. Molecular analysis of inflammatory markers in trauma patients at risk of postinjury complications. J Trauma. 2007;63:147-157; discussion 157-158.
27. Ami K, Kinoshita M, Yamauchi A, et al. IFN-gamma production from liver mononuclear cells of mice in burn injury as well as in postburn bacterial infection models and the therapeutic effect of IL-18. J Immunol. 2002;169:4437-4442.
28. G̈oebel A, Kavanagh E, Lyons A, et al. Injury induces deficient interleukin-12 production, but interleukin-12 therapy after injury restores resistance to infection. Ann Surg. 2000;231:253-261.
29. O'Suilleabhain C, O'Sullivan ST, Kelly JL, et al. Interleukin-12 treatment restores normal resistance to bacterial challenge after burn injury. Surgery. 1996;120:290-296.
30. Lyons A, Goebel A, Mannick JA, et al. Protective effects of early interleukin 10 antagonism on injury-induced immune dysfunction. Arch Surg. 1999;134:1317-1323; discussion 1324.
31. O'Riordain MG, O'Riordain DS, Molloy RG, et al. Dosage and timing of anti-TNF-alpha antibody treatment determine its effect of resistance to sepsis after injury. J Surg Res. 1996;64:95-101.
32. Gamelli RL, He LK, Liu H. Recombinant human granulocyte colonystimulating factor treatment improves macrophage suppression of granulocyte and macrophage growth after burn and burn wound infection. J Trauma. 1995;39:1141-1146; discussion 1146-1147.
33. Molloy RG, Holzheimer R, Nestor M, et al. Granulocyte-macrophage colonystimulating factor modulates immune function and improves survival after experimental thermal injury. Br J Surg. 1995;82:770-776.
34. Laffon M, Pittet JF, Modelska K, et al. Interleukin-8 mediates injury from smoke inhalation to both the lung endothelial and the alveolar epithelial barriers in rabbits. Am J Respir Crit Care Med. 1999;160:1443-1449.
35. Sakurai H, Soejima K, Schmalstieg FC, et al. Inhibition of lung permeability changes after burn and smoke inhalation by an anti-interleukin-8 antibody in sheep. Surg Today. 2009;39:399-406.
36. Polk HC, Jr, Cheadle WG, Livingston DH, et al. A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. Am J Surg. 1992;163:191-196.
37. Dries DJ. Interferon gamma in trauma-related infections. Intensive Care Med. 1996;22:S462-S467.
38. Wasserman D, Ioannovich JD, Hinzmann RD, et al. Interferon-gamma in the prevention of severe burn-related infections: a European phase III multicenter trial. The Severe Burns Study Group. Crit Care Med. 1998;26:434-439.
39. Park KH, Lee KH, Kim H, et al. The anti-inflammatory effects of ulinastatin in trauma patients with hemorrhagic shock. J Korean Med Sci. 2010;25:128-134.
40. Rodriguez JL, Miller CG, Garner WL, et al. Correlation of the local and systemic cytokine response with clinical outcome following thermal injury. J Trauma. 1993;34:684-694; discussion 694-695.
41. Finnerty CC, Herndon DN, Jeschke MG. Inhalation injury in severely burned children does not augment the systemic inflammatory response. Crit Care. 2007;11:R22.
42. Drost AC, Larsen B, Aulick LH. The effects of thermal injury on serum interleukin 1 activity in rats. Lymphokine Cytokine Res. 1993;12:181-185.
43. Cannon JG, Friedberg JS, Gelfand JA, et al. Circulating interleukin-1 beta and tumor necrosis factor-alpha concentrations after burn injury in humans. Crit Care Med. 1992;20:1414-1419.
44. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis. 1990;161:79-84.
45. Luger A, Graf H, Schwarz HP, et al. Decreased serum interleukin 1 activity and monocyte interleukin 1 production in patients with fatal sepsis. Crit Care Med. 1986;14:458-461.
46. Munoz C, Carlet J, Fitting C, et al. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest. 1991;88:1747-1754.
47. Mancilla J, García P, Dinarello CA. The interleukin-1 receptor antagonist can either reduce or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats. Infect Immun. 1993;61:926-932.
48. Silver GM, Gamelli RL, O'Reilly M, et al. The effect of interleukin 1 alpha on survival in a murine model of burn wound sepsis. Arch Surg. 1990;125:922-925.
49. O'Reilly M, Silver GM, Davis JH, et al. Interleukin 1 beta improves survival following cecal ligation and puncture. J Surg Res. 1992;52:518-522.
50. Kupper TS, Green DR, Durum SK, et al. Defective antigen presentation to a cloned T helper cell by macrophages from burned mice can be restored with interleukin-1. Surgery. 1985;98:199-206.
51. De Pablo R, Monserrat J, Reyes E, et al. Mortality in patients with septic shock correlates with anti-inflammatory but not proinflammatory immunomodulatory molecules. J Intensive Care Med. 2011;26:125-132.
52. Tadros T, Traber DL, Heggers JP, et al. Effects of interleukin-1alpha administration on intestinal ischemia and reperfusion injury, mucosal permeability, and bacterial translocation in burn and sepsis. Ann Surg. 2003;237:101-109.
53. Erdag G, Morgan JR. Interleukin-1alpha and interleukin-6 enhance the antibacterial properties of cultured composite keratinocyte grafts. Ann Surg. 2002;235:113-124.
54. Kampschmidt RF. Infection, inflammation, and interleukin 1 (IL-1). Lymphokine Res. 1983;2:97-102.
55. Oppenheim JJ, Charon JA, Luger TA. Evidence for an in vivo inflammatory role of interleukin 1 (IL 1). Transplant Proc. 1982;14:553-555.
56. Lipsky PE. Role of interleukin-1 in human B-cell activation. Contemp Top Mol Immunol. 1985;10:195-217.
57. Fibbe WE, Van Damme J, Billiau A, et al. Interleukin 1 induces human marrow stromal cells in long-term culture to produce granulocyte colony-stimulating factor and macrophage colony-stimulating factor. Blood. 1988;71:430-435.
58. Czuprynski CJ, Brown JF. Recombinant murine interleukin-1 alpha enhancement of nonspecific antibacterial resistance. Infect Immun. 1987;55:2061-2065.
59. Czuprynski CJ, Brown JF, Young KM, et al. Effects of murine recombinant interleukin 1 alpha on the host response to bacterial infection. J Immunol. 1988;140:962-968.
60. Ozaki Y, Ohashi T, Minami A, et al. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1a. Infect Immun. 1987;55:1436-1440.
61. Gladue R, Girard A, Newborg M. Enhanced antibacterial resistance in neutropenic mice treated with human recombinant interleukin-1 beta. Agents Actions. 1988;24:130-136.
62. Van der Meer JW, Helle M, Aarden L. Comparison of the effects of recombinant interleukin 6 and recombinant interleukin 1 on nonspecific resistance to infection. Eur J Immunol. 1989;19:413-416.
63. Van der Meer JW, Barza M, Wolff SM, et al. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci U S A. 1988;85:1620-1623.
64. Alexander HR, Doherty GM, Fraker DL, et al. Human recombinant interleukin-1 alpha protection against the lethality of endotoxin and experimental sepsis in mice. J Surg Res. 1991;50:421-424.
65. Parker KP, Benjamin WR, Kaffka KL, et al. Presence of IL-1 receptors on human and murine neutrophils. Relevance to IL-1-mediated effects in inflammation. J Immunol. 1989;142:537-542.
66. Sullivan GW, Carper HT, Sullivan JA, et al. Both recombinant interleukin-1 (beta) and purified human monocyte interleukin-1 prime human neutrophils for increased oxidative activity and promote neutrophil spreading. J Leukoc Biol. 1989;45:389-395.
67. Thomas JA, Tsen MF, White DJ, et al. IRAK contributes to burn-triggered myocardial contractile dysfunction. Am J Physiol Heart Circ Physiol. 2002;283:H829-H836.
68. Danis VA, Millington M, Hyland VJ, et al. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol. 1995;99:303-310.
69. Garat C, Arend WP. Intracellular IL-1Ra type 1 inhibits IL-1-induced IL-6 and IL-8 production in Caco-2 intestinal epithelial cells through inhibition of p38 mitogen-activated protein kinase and NF-kappaB pathways. Cytokine. 2003;23:31-40.
70. Drost AC, Burleson DG, Cioffi WG, Jr, et al. Plasma cytokines following thermal injury and their relationship with patient mortality, burn size, and time postburn. J Trauma. 1993;35:335-339.
71. Hack CE, De Groot ER, Felt-Bersma RJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood. 1989;74:1704-1710.
72. Gebhard F, Pfetsch H, Steinbach G, et al. Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch Surg. 2000;135:291-295.
73. S C, Mahadevan C, Thomas N, et al. Do baseline IL-6 levels predict postoperative morbidity after surgery (CABG) in cardiac patients? J Card Surg. 2006;21:521-522.
74. Tateishi Y, Oda S, Nakamura M, et al. Depressed heart rate variability is associated with high IL-6 blood level and decline in the blood pressure in septic patients. Shock. 2007;28:549-553.
75. Drost AC, Burleson DG, Cioffi WG, Jr, et al. Plasma cytokines after thermal injury and their relationship to infection. Ann Surg. 1993;218:74-78.
76. Gauglitz GG, Finnerty CC, Herndon DN, et al. Are serum cytokines early predictors for the outcome of burn patients with inhalation injuries who do not survive? Crit Care. 2008;12:R81.
77. Schl̈uter B, K̈onig B, Bergmann U, et al. Interleukin 6-a potential mediator of lethal sepsis after major thermal trauma: evidence for increased IL-6 production by peripheral blood mononuclear cells. J Trauma. 1991;31:1663-1670.
78. Ueyama M, Maruyama I, Osame M, et al. Marked increase in plasma interleukin-6 in burn patients. J Lab Clin Med. 1992;120:693-698.
79. Steensberg A, Fischer CP, Keller C, et al. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab. 2003;285:E433-E437.
80. Cicco NA, Lindemann A, Content J, et al. Inducible production of interleukin-6 by human polymorphonuclear neutrophils: role of granulocytemacrophage colony-stimulating factor and tumor necrosis factor-alpha. Blood. 1990;75:2049-2052.
81. Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998;101:311-320.
82. Guo Y, Dickerson C, Chrest FJ, et al. Increased levels of circulating interleukin 6 in burn patients. Clin Immunol Immunopathol. 1990;54:361-371.
83. Calandra T, Gerain J, Heumann D, et al. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med. 1991;91:23-29.
84. Chishti AD, Shenton BK, Kirby JA, et al. Neutrophil chemotaxis and receptor expression in clinical septic shock. Intensive Care Med. 2004;30:605-611.
85. Pawlik TM, Carter EA, Bode BP, et al. Central role of interleukin-6 in burn induced stimulation of hepatic amino acid transport. Int J Mol Med. 2003;12:541-548.
86. Zhang H, Wang HY, Bassel-Duby R, et al. Role of interleukin-6 in cardiac inflammation and dysfunction after burn complicated by sepsis. Am J Physiol Heart Circ Physiol. 2007;292:H2408-H2416.
87. Plackett TP, Gamelli RL, Kovacs EJ. Gender-based differences in cytokine production after burn injury: a role of interleukin-6. J Am Coll Surg. 2010;210:73-78.
88. Fontanilla CV, Faunce DE, Gregory MS, et al. Anti-interleukin-6 antibody treatment restores cell-mediated immune function in mice with acute ethanol exposure before burn trauma. Alcohol Clin Exp Res. 2000;24:1392-1399.
89. Gomez CR, Nomellini V, Baila H, et al. Comparison of the effects of aging and IL-6 on the hepatic inflammatory response in two models of systemic injury: scald injury versus i.p. LPS administration. Shock. 2009;31:178-184.
90. Carvalho GL, Wakabayashi G, Shimazu M, et al. Anti-interleukin-8 monoclonal antibody reduces free radical production and improves hemodynamics and survival rate in endotoxic shock in rabbits. Surgery. 1997;122:60-68.
91. Hack CE, Hart M, Van Schijndel RJ, et al. Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun. 1992;60:2835-2842.
92. Endo S, Inada K, Ceska M, et al. Plasma interleukin 8 and polymorphonuclear leukocyte elastase concentrations in patients with septic shock. J Inflamm. 1995;45:136-142.